QUAKER CHEMICAL CORPORATION (KWR): what the price assumes

In the published model solve dated 2026-Q2, anchored at $156.30, QUAKER CHEMICAL CORPORATION (KWR) is priced for +23.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-09-14 · Exported: 2026-09-15 · Source: https://boothcheck.com/report/KWR

Headline

FieldValue
TickerKWR
CompanyQUAKER CHEMICAL CORPORATION
Current price$156.30/sh
CompositionMetals (customer industry) 32% / Metalworking and other 68%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)4.9%
Operating margin today7.7%
Margin compression (value-band)-2.8pp
Implied growth23.9%
Multiple paid21x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: elevated (limited comparison data)

ReferenceValue
vs own history+0.15σ
cohort percentile (of 48 peers)79

Valuation X-Ray

The price is justified by relative-multiple; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.93x5expensive
Earnings1.46x3expensive
Relative1.13x5expensive
Growth1.35x3expensive

Families that justify the price: Relative Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.1%); the inversion above states its own rate.

Per-Model Detail (n=16)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$97.801.60xyesFCF base $0.1B, growth 8% (input: historical growth), terminal g 4.0%, WACC 7.1%, 5yr projection
DCF Exit MultipleGrowth$143.291.09xyesExit EV/EBITDA: 10.6x / 15.6x / 20.6x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$81.561.92xyesP/E 15.26x (blended: static sector reference 10x + trailing (TTM) 28x), scenarios: 11.4x / 15.3x / 18.3x (bear / base = reference held flat / bull), EV/EBITDA 8.88x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$61.362.55xyesBV/sh $80.03, ROE (TTM) 7.1%, ke 9.3%
Two-Stage Excess ReturnAsset$53.352.93xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$115.791.35xyesRev $2.0B, growth 8% (input: historical growth; tapered), Terminal P/S: 1.0x / 1.4x / 1.6x (bear / base = today's held flat / bull, cap 6x)
Peter Lynch Fair ValueRelative$195.650.80xyesEPS $5.59, growth 35% (input: historical EPS growth), PEG=0.79 (Undervalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$107.361.46xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.25B × (1−21%) / WACC 7.1% → EPV (no growth)
Residual IncomeAsset$52.183.00xyesBV $80.03 + 5yr PV of (ROE (TTM) 7.1% − Kₑ 9.3%) × BV; BV grows 4.6%/yr
Graham NumberAsset$100.331.56xyes√(22.5 × EPS $5.59 × BVPS $80.03) — Graham's conservative floor
EV/EBITDA RelativeRelative$32.624.79xyesEBITDA $0.22B × sector EV/EBITDA 6.0x
FCF YieldEarnings$2.1971.37xyesFCF $74.6M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.0115630.00xyesSBC-adj FCF $0.06B (FCF $0.07B − SBC $0.01B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$180.370.87xyesEPS $5.59 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$16.859.28xyesBV $80.03 × (ROIC 1.5% / WACC 7.1%)
P/Sales SectorRelative$137.751.13xyesRevenue $1.98B × sector P/S 1.2x
PEG Fair ValueRelative$209.630.75xyesEPS $5.59 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$60.432.59xyesEPS $5.59 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$736.7m
Net debt / NOPAT (after-tax)6.13x
Net debt / operating income (pre-tax)4.84x
Interest coverage3.8x
Share count CAGR (buyback)-0.9%
Burning cashno

Bullet Takeaways

Bull Case

Read Quaker Houghton at its current stage: a mature specialty-chemicals supplier at a cyclical low point in its end markets, where the bet is recovery toward normal rather than a growth story. The 10-K describes serving customers in "the steel, automotive, aerospace, industrial equipment, aluminum, and durable goods industries," and those industries set the demand for its fluids. The most recent quarter showed the business is outperforming a weak backdrop: net sales rose 8% to $480.5 million, organic volumes grew 3%, and the company estimated its end markets actually declined about 1%, meaning the growth came from net share gains. A supplier taking share while its markets shrink is winning on the merits, not on the cycle.

The moat is customer intimacy, which is the quiet strength of the model. Quaker Houghton's fluids are a small fraction of a customer's cost but central to keeping a steel mill or an auto plant running, and the company is embedded in customers' operations through chemical-management services. The 10-K notes that where it acts as an agent ordering goods for customers, it recognizes revenue on the administrative fee earned, a sign of how deeply it sits inside customer procurement. Switching a process fluid means requalifying it across a production line, which customers avoid unless something breaks, so the revenue is sticky and the relationships are long. Gross margin near 36.8%, at the high end of the company's target range, reflects that pricing power.

The self-help story is the lever the bull case leans on hardest. Management launched a transformation program targeting adjusted EBITDA margins of 18% or more, with roughly $10 million of run-rate savings in 2026 and $20 million to $30 million over three years. With the most recent quarter marking a third consecutive quarter of adjusted EBITDA growth and Asia Pacific posting double-digit organic volume gains, the operating momentum is building before the end-market cycle even turns. The balance sheet supports the plan: net debt near $742 million is moderate at interest coverage of 3.5 times. Against peer Valvoline and the broader specialty-chemicals group, Quaker Houghton's share gains plus a margin-improvement program plus eventual cyclical recovery is a three-part case, and the price is paying for normalized economics rather than a permanent trough.

Bear Case

The external variable with the most leverage on Quaker Houghton is the industrial cycle it cannot control, and the price already assumes that cycle cooperates. The company's fluids demand is a derivative of steel, automotive, and aerospace production, so when those industries slow, Quaker's volumes follow, and trailing operating profit is currently depressed for exactly that reason, with an operating margin of just 3.1% against a through-the-cycle level near 8.1%. The valuation reads reasonable only because it normalizes to that mid-cycle margin; if the industrial recovery stalls or a global slowdown deepens, the earnings the price assumes do not materialize, and a 21-times multiple on earnings that stay at trough is far less defensible.

Input costs and macro shocks are the near-term pressure, and they are live. Management has flagged that gross margins face temporary pressure in the second quarter from higher input costs tied to Middle East conflict, expecting to recover to target only as it exits the year. A specialty-chemicals maker buys petroleum-derived feedstocks, so an oil-price spike or a supply-chain disruption squeezes the margin before the company can pass it through, and the 10-K warns that suppliers "may experience similar conditions, which could impact their ability to fulfill their obligations to us" with adverse effects on results. The adjusted EBITDA margin already slipped 50 basis points in the quarter on higher costs, so the pressure is not hypothetical.

The concentration in a handful of heavy industries is the structural fragility. The 10-K notes that a slowdown "in production at one or more of these locations or other major sites of a significant customer could have a material adverse effect on our business," which is the flip side of customer intimacy: deep embedment in a few large customers means a single plant closure or a customer's downturn flows straight to Quaker's revenue. Net debt near $742 million is over four times mid-cycle operating income, manageable in good times but a constraint if the cycle worsens and the cash flow that services it thins. The bear case is not that Quaker is a weak business; it is that the price already credits a normalized margin and a successful transformation program, leaving little cushion if the industrial cycle, input costs, or a key customer disappoints.

Valuation

The price is making a normalization-and-self-help bet, and reading it correctly requires looking past the depressed trailing earnings. On its through-the-cycle margin, the market pays roughly 21 times Quaker Houghton's normalized operating income, which inverts to about 25% annual operating-profit growth over five years. That headline growth rate sounds aggressive, but it is largely the math of recovering from a cyclical trough, with the trailing margin at 3.1% against a mid-cycle level near 8.1%: most of the implied growth is margin recovery toward normal, not unprecedented expansion, and the company has recently delivered that kind of pace. About 34% of comparable companies have sustained it over five years, a moderate base rate.

The trailing earnings make the static method families read the price as expensive, and that distinction matters. Measured against depressed trailing operating income, the asset-value, earnings-power, and peer-multiple lenses all sit well below the price, because a single trough year of earnings cannot support the multiple. Normalized to the mid-cycle margin, the picture is far more reasonable, which is why the priced-in assumption reads as broadly consistent with plausible recovery rather than as a stretch. The honest framing is that this is a cyclical whose trailing numbers understate its earnings power, so the apparent richness is a function of where in the cycle the measurement lands, not of the price overreaching on normal economics.

Solvency is moderate and bears on the downside. Net debt near $742 million is about four to six times operating income depending on whether you use the trough or the normalized figure, with interest coverage of 3.5 times, adequate but not generous for a cyclical business carrying that leverage into a soft patch. The valuation rests on the margin recovering toward mid-cycle plus the transformation program delivering its targeted savings, and on the company continuing to gain share against a flat-to-declining market. Against peer Valvoline, Quaker trades on the expectation of that recovery, and a street mean target near $163 to $174 sits above today's price. The gap reflects the street crediting the cyclical recovery and the cost program that the trailing-earnings methods cannot extend, which is the same normalization bet the inversion frames.

Catalysts

The first-quarter 2026 print, reported in early May, showed the share-gain story working against a soft market. Net sales rose 8% to $480.5 million, ahead of expectations, with organic volumes up 3% even as the company estimated its end markets declined about 1%, and non-GAAP diluted EPS came in at $1.63. Gross margin reached 36.8%, near the top of the 36% to 37% target range and up sequentially, marking a third consecutive quarter of adjusted EBITDA growth with double-digit organic volume gains in Asia Pacific.

The margin trajectory is the catalyst with two sides. Management launched a transformation program targeting adjusted EBITDA margins of 18% or more, with roughly $10 million of run-rate savings in 2026 and $20 million to $30 million over three years, which is the structural lever on profitability. Against it, the company flagged temporary gross-margin pressure in the second quarter from higher input costs tied to Middle East conflict, expecting to recover to target as it exits the year. The interplay between the cost-savings program and the input-cost headwind is what determines the margin path through 2026.

The sell side is constructive. The consensus rating sits at Buy, with a mean price target near $163 to $174 above today's price and a range from roughly $120 to $205. The targets above the price reflect the street crediting both the cyclical recovery in industrial end markets and the margin-improvement program, so the next several quarters of volume and margin prints are the catalysts that decide whether that optimism is earned.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Quaker Houghton Q1 2026 results, May 2026 · MarketBeat and analyst consensus, 2026 · Quaker Houghton transformation program, May 2026 · MarketBeat and analyst coverage, 2026

View the full interactive KWR report on boothcheck